DGTI 2024
ProgrammePostersPeople
Search
  • EN
All people

Jan-Henning Klusmann

Date

Further involvements

  • 12/09/2024
    09:30 – 09:45 12 Min. 3 Min.
    • Abstract lecture (Abstract winner)
    The deletion of the immune checkpoint inhibitor receptor NKG2A with CRISPR/Cas9 improved the anti-leukemic efficacy of primary CD33-targeting CAR-NK cells

    Der Knockout des Immun-Checkpoint-Inhibitor-Rezeptors NKG2A mit CRISPR/Cas9 verbessert die antileukämische Wirksamkeit von primären CD33-CAR NK Zellen

     Immunotherapy and Gene Therapy
    • v1.25.2
    • © Conventus Congressmanagement & Marketing GmbH
    • Imprint
    • Privacy

Cookie settings

We use cookies on our website. Cookies are small (text) files that are created and stored on your device (e.g., smartphone, notebook, tablet, PC). Some of these cookies are technically necessary to operate the website, other cookies are used to extend the functionality of the website or for marketing purposes. Apart from the technically necessary cookies, you are free to allow or not allow cookies when visiting our website.

Imprint | Privacy